Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilonacept in non-dialysis chronic kidney disease and anemia
NCT00609544Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anemia comparing Rilonacept Arm with Placebo Arm (2 arms). Primary endpoint: Change in blood hemoglobin concentration at 12 weeks. Status: withdrawn.
02
Drugs
rilonacept
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00609544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609544.